NBIX · CIK 0000914475 · operating
Neurocrine Biosciences discovers, develops, and commercializes pharmaceuticals targeting neurological, psychiatric, endocrine, and immunological disorders. The company operates across multiple therapeutic areas with an established product portfolio and a pipeline of candidates in clinical development. Its marketed products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease, Orilissa for endometriosis, Oriahnn for uterine fibroids, and CRENESSITY for congenital adrenal hyperplasia, alongside additional products commercialized under the ALKINDI and Efmody brands.
The clinical pipeline includes candidates targeting movement disorders, major depressive disorder, schizophrenia, bipolar mania, Alzheimer's disease, epilepsy, and obesity. The company maintains license and collaboration agreements with pharmaceutical partners including Takeda, Sanofi, AbbVie, Voyager Therapeutics, and Xenon Pharmaceuticals, among others, which support both development activities and revenue generation through milestone payments and royalties.
Incorporated in Delaware and headquartered in San Diego, California, the company operates with approximately 2,000 full-time employees and maintains a presence across multiple geographic markets internationally. The company is publicly traded on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $4.67 | $4.81 | +41.9% | |
| 2024 | $3.29 | $3.40 | +33.2% | |
| 2023 | $2.47 | $2.56 | +58.3% | |
| 2022 | $1.56 | $1.61 | +69.6% | |
| 2021 | $0.92 | $0.95 | -74.3% | |
| 2020 | $3.58 | $3.72 | +922.9% | |
| 2019 | $0.35 | $0.37 | +84.2% | |
| 2018 | $0.19 | $0.20 | +171.4% | |
| 2017 | $0.07 | $0.08 | +104.3% | |
| 2016 | $-1.63 | $-1.63 | -55.2% | |
| 2015 | $-1.05 | $-1.05 | -29.6% | |
| 2014 | $-0.81 | $-0.81 | -406.3% | |
| 2013 | $-0.16 | $-0.16 | -214.3% | |
| 2012 | $0.14 | $0.14 | -79.1% | |
| 2011 | $0.67 | $0.68 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-11 | 0000914475-26-000007 | SEC ↗ |
| 2024-12-31 | 2025-02-10 | 0000914475-25-000037 | SEC ↗ |
| 2023-12-31 | 2024-02-09 | 0000914475-24-000054 | SEC ↗ |
| 2022-12-31 | 2023-02-09 | 0000914475-23-000011 | SEC ↗ |
| 2021-12-31 | 2022-02-11 | 0000914475-22-000013 | SEC ↗ |
| 2020-12-31 | 2021-02-05 | 0000914475-21-000020 | SEC ↗ |
| 2019-12-31 | 2020-02-07 | 0001564590-20-003773 | SEC ↗ |
| 2018-12-31 | 2019-02-08 | 0001564590-19-002328 | SEC ↗ |
| 2017-12-31 | 2018-02-13 | 0001193125-18-042794 | SEC ↗ |
| 2016-12-31 | 2017-02-14 | 0001193125-17-043838 | SEC ↗ |